Best Blue Chip Stocks To Watch Right Now

Despite a positive start, stocks fell off after opening and the Dow Jones Industrial Average (DJINDICES: ^DJI  ) finished down 0.16%, or 26 points. It was the blue chips' fifth straight session with little movement, as investors seem to be unsure if the market deserves to go further into record territory with earnings continuing to roll in. June new home sales topped expectations, coming at 497,000 versus estimates of 483,000, but Wall Street seemed to be unimpressed by President Obama's remarks on the economy. In his address, Obama touted mostly recycled ideas such as investing in infrastructure and raising the minimum wage that have gained little traction in the divided Congress.

Two industrial powerhouses on the Dow delivered earnings today. First, Caterpillar (NYSE: CAT  ) shares finished down 2.4% after missing estimates as many had expected. The slowdown in Chinese construction has hurt demand for materials and thus mining equipment, a key component of Caterpillar's business. The world's largest maker of earth-moving equipment said profits fell 43% as EPS came in at $1.45, down from $2.54 a year ago, and worse than estimates at $1.69. Revenue dropped 15.8% to $14.6 billion, below expectations of $15.1 billion. Management promised cost-cutting to cope with the decrease in demand, and cut its full-year EPS outlook from $7 to $6.50.

Best Blue Chip Stocks To Watch Right Now: Syngas Ltd(SYS.AX)

Syngas Limited operates in the energy sector in Australia. It engages in the development of ground coal to liquid projects in South Australia, Victoria, and Queensland. The company?s Clinton project is involved in the development, commissioning, and operation of diesel production facility in Adelaide city in South Australia. It also develops a biomass (renewable) project, including a 5MW biomass to power project in Wagga Wagga, New South Wales. In addition, the company holds interests in the Moorlands coal deposit in Adelaide; and the Victorian Lignite project, as well as rights to earn interest in four oil and gas prospects in the Gulf of Mexico. Syngas Limited is based in Melbourne, Australia.

Best Blue Chip Stocks To Watch Right Now: Saferoads Holdings Ltd (SRH.AX)

Saferoads Holdings Limited manufactures, imports, and distributes road safety products and solutions for motorists, road construction workers, and pedestrians primarily in Australia and New Zealand. The company provides civil and road safety products and barriers, including box beam rail guards, guard rails, motorcycle rub rails, and omnistop end terminals; and guardrail installations, wire rope installations, crash cushion installations, traffic calming installation, minor bridge works, bridge rails, noise walls, technical support, ongoing location inspections, traffic management, emergency repairs of guardrail and wire rope safety barriers, programmed guardrail, and wire rope safety barrier maintenance services for civil projects. It also offers guide posts that includes 1M tapered bollards, dig in rubber guide posts, econo dig in and econo guide posts, edge marker posts, short term bollards, snaploc bridge mounts and guide posts, supa drive post sockets and rubber guide posts, and T-top bollards; crash cushions, including non deforming bollards, omni stop bollards, and rubber crash cushion; and electronic traffic equipment, such as variable message boards. In addition, the company provides traffic calming products, including grass infills for roundabouts, roll out speed humps, rubber kerbing, rubber lane markers, rubber roundabouts, rubber speed cushions, rubber speed humps, rumble bars, safecycle, and wheel stops; traffic signals, push buttons, and lanterns; and public lighting, flag poles, and street sign posts, such as banners and flag poles, vic roads slips, safe poles, and street sign poles. Further, the company offers safety barriers for road users, pedestrians, cyclists, and motorcycles, including blockout pedestrian barriers, ironman barrier TL4, ironman median gate, and T-Lok barrier. It serves state government departments, local councils, and road construction companies. The company was founded in 1992 and is headquartered in Dro uin, Australia.

Top 5 Value Stocks To Watch Right Now: Galena Biopharma Inc (GALE)

Galena Biopharma, Inc. (Galena), formerly RXi Pharmaceuticals Corporation, incorporated on April 3, 2006, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics. The Company is pursuing the development of cancer therapeutics using peptide-based immunotherapy products, including its main product candidate, NeuVaxTM (E75), for the treatment of breast cancer and other tumors. NeuVax is a peptide-based immunotherapy intended to reduce the recurrence of breast cancer in low-to-intermediate HER2-positive breast cancer patients not eligible for trastuzumab (Herceptin; Genentech/Roche). On January 19, 2012, the Company initiated enrollment in its Phase 3 PRESENT clinical trial for NeuVax (E75 peptide plus GM-CSF) vaccine in low-to-intermediate HER2 1+ and 2+ breast cancer patients in the adjuvant setting to prevent recurrence (Clinicaltrials.gov identifier NCT01479244). The Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment study is a randomized, multicenter, multinational clinical trial that will enroll approximately 700 breast cancer patients. The Company�� Phase 2 trial of NeuVax achieved its primary endpoint of disease-free survival (DFS). On April 13, 2011, the Company completed its acquisition of Apthera, Inc.,(Apthera).

The Company focuses to start a Phase 2 trial comparing NeuVax in combination with trastuzumab (Herceptin) versus trastuzumab, alone, in a 300-patient, randomized study in the adjuvant breast cancer setting. The Company's second product candidate, Folate Binding Protein-E39 (FBP), is a vaccine, consisting of the peptides E39 and J65, aimed at preventing the recurrence of ovarian, endometrial, and breast cancers. On February 14, 2012, the Company announced the initiation of a Phase 1/2 clinical trial in two gynecological cancers: ovarian and endometrial adenocarcinomas. Folate binding protein has ! very limited tissue distribution and expression in non-malignant tissue and is over-expressed in more than 90% of ovarian and endometrial cancers, as well as in 20% to 50% of breast, lung, colorectal and renal cell carcinomas.

In April 2011, the Company acquired Apthera Inc and its NeuVax product candidate. The Company focuses on developing a pipeline of immunotherapy product candidates for the treatment of various cancers based on the E75 peptide, the advanced of which is NeuVax, which is targeted at preventing the recurrence of breast cancer. NeuVax has had positive Phase 1/2 clinical trial results for the prevention of breast cancer recurrence in patients who have had breast cancer and received the standard of care treatment (surgery, chemotherapy, radiotherapy and hormonal therapy as indicated). The Company had also initiated its Phase 3 PRESENT clinical trial of NeuVax for the prevention of breast cancer recurrence in early-stage low-to-intermediate HER2 breast cancer patients. NeuVax directs killer T-cells to target and destroy cancer cells that express HER2/neu, a protein associated with epithelial tumors in breast, ovarian, pancreatic, colon, bladder and prostate cancers. NeuVax is comprised of a HER2/neu-derived peptide called E75. E75 is a nine-amino acid sequence that is immunogenic (produces an immune response) and GM-CSF is a commercially available protein that acts to stimulate and activate components of the immune system such as macrophages and dendritic cells.

The Company also develops novel applications for NeuVax based on preclinical studies and phases 2 clinical trials which suggest that combining NeuVax and trastuzumab (Herceptin; Genentech/Roche) can increase antigen presentation by tumor cells by promoting receptor internalization and subsequent proteosomal degradation of the HER2 protein. The Company also is pursuing additional therapeutic indications for NeuVax that are in Phase 1/2 clinical trials. RXI-109, is a dermal anti-scarring therapy that targets! connecti! ve tissue growth factor (CTGF) and that may inhibit connective tissue formation in human fibrotic disease.

The Company competes with Roche Laboratories, Inc., Pfizer Inc., Bayer HealthCare AG, Sanofi-Aventis, US, LLC, Amgen, Inc., GlaxoSmithKline plc, Renovo Group plc, CoDa Therapeutics, Inc., Sirnaomics, Inc., FirstString Research, Inc., Merz Pharmaceuticals, LLC, Capstone Therapeutics, Halscion, Inc., Garnet Bio Therapeutics, Inc., AkPharma Inc., Promedior, Inc., Kissei Pharmaceutical Co., Ltd., Eyegene, Derma Sciences, Inc., Healthpoint Biotherapeutics, Pharmaxon, Excaliard Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Marina Biotech, Inc., Tacere Therapeutics, Inc., Benitec Limited, OPKO Health, Inc., Silence Therapeutics plc, Quark Pharmaceuticals, Inc., Rosetta Genomics Ltd., Lorus Therapeutics, Inc., Tekmira Pharmaceuticals Corporation, Arrowhead Research Corporation, Regulus Therapeutics Inc. and Santaris.